Abstract

BackgroundArginine is a high-value product, especially for the pharmaceutical industry. Growing demand for environmental-friendly and traceable products have stressed the need for microbial production of this amino acid. Therefore, the aim of this study was to improve arginine production in Escherichia coli by metabolic engineering and to establish a fermentation process in 1-L bioreactor scale to evaluate the different mutants.ResultsFirstly, argR (encoding an arginine responsive repressor protein), speC, speF (encoding ornithine decarboxylases) and adiA (encoding an arginine decarboxylase) were knocked out and the feedback-resistant argA214 or argA215 were introduced into the strain. Three glutamate independent mutants were assessed in bioreactors. Unlike the parent strain, which did not excrete any arginine during glucose fermentation, the constructs produced between 1.94 and 3.03 g/L arginine. Next, wild type argA was deleted and the gene copy number of argA214 was raised, resulting in a slight increase in arginine production (4.11 g/L) but causing most of the carbon flow to be redirected toward acetate. The V216A mutation in argP (transcriptional regulator of argO, which encodes for an arginine exporter) was identified as a potential candidate for improved arginine production. The combination of multicopy of argP216 or argO and argA214 led to nearly 2-fold and 3-fold increase in arginine production, respectively, and a reduction of acetate formation.ConclusionsIn this study, E. coli was successfully engineered for enhanced arginine production. The ∆adiA, ∆speC, ∆speF, ∆argR, ∆argA mutant with high gene copy number of argA214 and argO produced 11.64 g/L of arginine in batch fermentation, thereby demonstrating the potential of E. coli as an industrial producer of arginine.

Highlights

  • Arginine is a high-value product, especially for the pharmaceutical industry

  • The literature concerning E. coli and arginine biosynthesis has mainly been focused on the genetics and regulation systems rather than the production

  • The strain C600+Δ4 carrying either plasmid pKH15 or pKH19 could not be grown on M9 minimal media containing IPTG without exogenous glutamate supplementation and only weak growth was observed on the same medium when both glutamate and IPTG were absent

Read more

Summary

Introduction

Arginine is a high-value product, especially for the pharmaceutical industry. The aim of this study was to improve arginine production in Escherichia coli by metabolic engineering and to establish a fermentation process in 1-L bioreactor scale to evaluate the different mutants. Given the wide utilization of arginine, there is a significant industrial demand for this amino acid, especially from sources that can guarantee an environmentally and Ginesy et al Microbial Cell Factories (2015) 14:29 processes, and its well characterized metabolism and available molecular tools for genetic engineering, render it an organism of interest for the production of arginine. A number of patents regarding arginine production by E. coli strains exist The literature concerning E. coli and arginine biosynthesis has mainly been focused on the genetics and regulation systems rather than the production

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call